East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Sevelamer Hydrochloride Tablets 400 mg and 800 mg. Aurobindo Pharma’s Sevelamer Hydrochloride Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), RENAGEL® Tablets manufactured by Genzyme Corporation.

Sevelamer Hydrochloride Tablets are indicated for:

• The control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.